AlphaCore Capital
ONCY icon

AlphaCore Capital’s Oncolytics Biotech ONCY Stock Holding History

AlphaCore Capital’s Portfolio ONCY Stock Details ONCY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$11.9K Hold
12,500
– – ﹤0.01% 1390
2026
Q1 		$10.6K Sell
12,500
-10,000
-44% -$9.9K ﹤0.01% 1111
2025
Q4 		$19.7K Buy
+22,500
New +$24.3K ﹤0.01% 1260

Other funds holding ONCY

Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
XTX Topco
XTX Topco George Town, Cayman Islands $7.72B AUM 32.88% 1-Year Est. Return
Seeds Investor
Seeds Investor New York $973M AUM 33.7% 1-Year Est. Return
IAIM
International Assets Investment Management Orlando, Florida $1.67B AUM 28.26% 1-Year Est. Return
Connective Capital Management
Connective Capital Management Palo Alto, California $142M AUM 51.29% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Tocqueville Asset Management
Tocqueville Asset Management New York $7.56B AUM 44.87% 1-Year Est. Return
Everhart Financial Group
Everhart Financial Group Dublin, Ohio $1.62B AUM 25.73% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return
PFG Investments
PFG Investments Woodbury, New York $2.58B AUM 36.93% 1-Year Est. Return

AlphaCore Capital's ONCY Position: Q2 2026 in Review

AlphaCore Capital held its Oncolytics Biotech (ONCY) position steady in Q2 2026 at 12,500 shares worth $11.9K. The position accounts for ﹤0.01% of the portfolio, ranked #1390.

AlphaCore Capital first reported a position in ONCY in Q4 2025 and has held it in 3 quarters since. The position peaked at $19.7K in Q4 2025. 76 funds tracked by Wall St. Rank hold ONCY as of Q2 2026.

  • AlphaCore Capital held 12,500 shares of Oncolytics Biotech worth $11.9K as of Q2 2026.
  • AlphaCore Capital left its Oncolytics Biotech share count unchanged in Q2 2026.
  • Oncolytics Biotech made up ﹤0.01% of AlphaCore Capital's portfolio in Q2 2026, its #1390 holding.
  • AlphaCore Capital first reported a position in Oncolytics Biotech in Q4 2025 and has held it in 3 quarters since.
  • AlphaCore Capital's Oncolytics Biotech position peaked at $19.7K in Q4 2025.
  • 76 funds tracked by Wall St. Rank held Oncolytics Biotech as of Q2 2026.

Based on AlphaCore Capital's 13F filing for Q2 2026, filed 6 Aug 2026.